First Quarter 2018 Investor Presentation
Investor Presentation
First three months of 2018
Slide 18
Closing remarks
Solid leadership positions and continued
market opportunities
27% Novo Nordisk value market share in diabetes
care and solid leadership position
~5% insulin market volume growth
45%
>21%
54%
Novo Nordisk insulin volume market share
with leadership position across all regions
GLP-1 volume market growth
38%
Novo Nordisk GLP-1 volume market share
with global leadership position
SaxendaⓇ value market share with a global
leadership in the anti obesity market
Promising pipeline and product launches
• The only company with a full portfolio of novel
insulin and GLP-1 products
•
.
Semaglutide portfolio offers expansion opportunity
with both once-weekly OzempicⓇ and oral
administration
XultophyⓇ supports promising outlook for insulin
and GLP-1 combination therapy
• SaxendaⓇ and multiple clinical stage development
projects hold potential within obesity
• Broad pipeline within haemophilia
Source: IQVIA MAT Feb 2018 volume and value (DKK) figures
changing
diabetes
novo nordiskView entire presentation